Scrapping Its IPO, Phenomix Teams Up With Forest
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal funds ongoing clinical development of dutogliptin and provides a cushion in difficult financial times.
You may also be interested in...
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.
Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
In same-day earnings call, the specialty pharma company reported year-end fiscal 2010 sales of $4.2 billion, up 6.9 percent.